ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions.

Theodore James Jr. Washburn, the Principal Accounting Officer at Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), recently sold 2,272 shares of common stock. The shares were sold at a price of $34.39 each, ...

Rejecting allegations from the White House that her administration has ties to criminal organisations, Sheinbaum shifted the ...

"It is very important for the people of Mexico to know that we will always defend the dignity of our people, that we will ...

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.4 billion focused on developing and commercializing novel therapies for cancer treatment, stands at a ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

Introduction An organ transplant is a surgical procedure replacing a damaged organ with a healthy one. Diagnostics for organ transplants are cl ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

The FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA ...

The US Food and Drug Administration (FDA) has accepted for priority review a supplemental new drug application (sNDA) for ...